Lilly Bets $2.8 Billion on Psychedelics as Depression Treatment Becomes a Big Pharma Contest

Psychiatric drug development has long been constrained by limited efficacy, slow onset of action, and high failure rates. Now, psychedelics are moving from high-risk trials at small biotech companies into the core investment portfolios of large pharmaceutical companies. Lilly has agreed to acquire AtaiBeckley for approximately $2.8 billion in cash, a deal that not only expands its neuroscience pipeline but also represents one of the largest recent investments by a major pharmaceutical company in psychedelic therapies.

The two parties signed a merger agreement on July 15, which AtaiBeckley’s board of directors unanimously approved. According to documents filed with the U.S. Securities and Exchange Commission, Lilly will pay $6.75 per share at closing, representing a total equity value of approximately $2.8 billion. Shareholders may also receive contingent value rights worth up to $2.50 per share, amounting to approximately $1 billion in additional consideration if all milestones are achieved. The $2.8 billion therefore represents cash payable at closing, not the full amount that could ultimately be paid under the transaction.

The acquisition centers on BPL-003, an intranasally administered mebufotenin benzoate, a synthetic form of 5-MeO-DMT, primarily being developed for treatment-resistant depression. The candidate has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and has begun Phase 3 development activities. According to the company’s reported late-stage Phase 2 study, improvements in patients’ depressive symptoms lasted for several months following an in-clinic treatment session averaging approximately two hours. However, complete Phase 3 efficacy and safety results, as well as comparisons with current treatments, have yet to be obtained.

AtaiBeckley’s second major asset, VLS-01, is a DMT film absorbed through the oral mucosa and is currently undergoing a late-stage Phase 2 trial. The transaction terms tie additional payments directly to the success or failure of the two drugs: VLS-01 must begin a Phase 3 trial within four years after closing; BPL-003 and VLS-01 must obtain U.S. approval within five and seven years, respectively, and complete adjustments to their controlled-substance classifications by the U.S. Drug Enforcement Administration. This structure leaves a substantial portion of the clinical and regulatory risk for the future.

Whether psychedelics can become widely accessible psychiatric treatments depends on more than efficacy alone. These therapies often need to be administered in supervised medical settings, and the time spent in the clinic, treatment frequency, staffing, and reimbursement model will all affect commercial viability. Chemical industry media cited analysts estimating that BPL-003 may eventually require only four to six treatments per year, fewer than the potentially frequent dosing required for Johnson & Johnson’s Spravato. However, this remains a commercial estimate and cannot replace head-to-head trials or real-world data after approval.

The transaction is expected to close in the third quarter, subject to approval by AtaiBeckley shareholders and regulatory authorities. If the agreement is terminated under certain circumstances, AtaiBeckley must pay $104.3 million. Lilly is acquiring more than several compounds; it is buying a clinical concept for turning psychedelic experiences into standardized psychiatric treatment regimens. Whether that concept ultimately proves viable will still depend on Phase 3 evidence, long-term safety, controlled-substance rules, and whether healthcare systems can support the corresponding care processes.